Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Gains from Sales and Divestitures (2016 - 2023)

Historic Gains from Sales and Divestitures for Editas Medicine (EDIT) over the last 8 years, with Q2 2023 value amounting to $210701.0.

  • Editas Medicine's Gains from Sales and Divestitures fell 946.08% to $210701.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $210701.0, marking a year-over-year decrease of 946.08%. This contributed to the annual value of $286642.0 for FY2022, which is 724.89% up from last year.
  • According to the latest figures from Q2 2023, Editas Medicine's Gains from Sales and Divestitures is $210701.0, which was down 946.08% from $146209.0 recorded in Q1 2023.
  • Editas Medicine's 5-year Gains from Sales and Divestitures high stood at $304638.0 for Q4 2020, and its period low was $18000.0 during Q1 2019.
  • Moreover, its 5-year median value for Gains from Sales and Divestitures was $200888.0 (2021), whereas its average is $179748.3.
  • In the last 5 years, Editas Medicine's Gains from Sales and Divestitures crashed by 8269.65% in 2019 and then surged by 108551.67% in 2020.
  • Over the past 5 years, Editas Medicine's Gains from Sales and Divestitures (Quarter) stood at $99919.0 in 2019, then soared by 204.88% to $304638.0 in 2020, then decreased by 12.27% to $267268.0 in 2021, then rose by 7.25% to $286642.0 in 2022, then decreased by 26.49% to $210701.0 in 2023.
  • Its Gains from Sales and Divestitures stands at $210701.0 for Q2 2023, versus $146209.0 for Q1 2023 and $286642.0 for Q4 2022.